3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Myeloid Malignancy
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
130
Cyclophosphamide
41
Bendamustine Hydrochloride
39
venetoclax
25
fludarabine
25
obinutuzumab
24
Lenalidomide
23
ibrutinib
22
Gemcitabine
22
Vincristine
20
Prednisone
20
tositumomab I-131
19
Doxorubicin
19
plerixafor
14
Dexamethasone
14
Granulocyte Colony-Stimulating Factor
12
pirtobrutinib
11
Brentuximab Vedotin
11
glofitamab
10
tocilizumab
9
pembrolizumab
9
ibritumomab tiuxetan
9
Etoposide
9
Azacitidine
9
polatuzumab vedotin
8
parsaclisib
8
copanlisib
8
acalabrutinib
8
Drug Therapy
8
ublituximab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Non-Hodgkin
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts